Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

TRP channels as targets for therapeutic intervention in obesity: focus on TRPV1 and TRPM5.

Palmer RK, Lunn CA.

Curr Top Med Chem. 2013;13(3):247-57. Review.

PMID:
23432058
2.

A new look at membrane protein binding.

Lunn CA.

Nat Biotechnol. 2011 Apr;29(4):328-9. doi: 10.1038/nbt.1820. No abstract available.

PMID:
21478848
3.

Label-free screening assays: a strategy for finding better drug candidates.

Lunn CA.

Future Med Chem. 2010 Nov;2(11):1703-16. doi: 10.4155/fmc.10.246. Review.

PMID:
21428840
4.

Expansion of SAR studies on triaryl bis sulfone cannabinoid CB2 receptor ligands.

Tong L, Shankar BB, Chen L, Rizvi R, Kelly J, Gilbert E, Huang C, Yang DY, Kozlowski JA, Shih NY, Gonsiorek W, Hipkin RW, Malikzay A, Lunn CA, Lundell DJ.

Bioorg Med Chem Lett. 2010 Nov 15;20(22):6785-9. doi: 10.1016/j.bmcl.2010.08.126. Epub 2010 Aug 31.

PMID:
20850969
5.

Membrane proteins as drug targets. Preface.

Lunn CA.

Prog Mol Biol Transl Sci. 2010;91:xi. doi: 10.1016/S1877-1173(10)91012-0. No abstract available.

PMID:
20691956
6.
7.

Screening for antibacterial inhibitors of the UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) using a high-throughput mass spectrometry assay.

Langsdorf EF, Malikzay A, Lamarr WA, Daubaras D, Kravec C, Zhang R, Hart R, Monsma F, Black T, Ozbal CC, Miesel L, Lunn CA.

J Biomol Screen. 2010 Jan;15(1):52-61. doi: 10.1177/1087057109355319. Epub 2009 Dec 17.

PMID:
20019290
8.

Non-aromatic A-ring replacement in the triaryl bis-sulfone CB2 receptor inhibitors.

Gilbert EJ, Zhou G, Wong MK, Tong L, Shankar BB, Huang C, Kelly J, Lavey BJ, McCombie SW, Chen L, Rizvi R, Dong Y, Shu Y, Kozlowski JA, Shih NY, Hipkin RW, Gonsiorek W, Malikzay A, Lunn CA, Favreau L, Lundell DJ.

Bioorg Med Chem Lett. 2010 Jan 15;20(2):608-11. doi: 10.1016/j.bmcl.2009.11.084. Epub 2009 Nov 22.

PMID:
20005710
9.

Characterizing cannabinoid CB2 receptor ligands using DiscoveRx PathHunter beta-arrestin assay.

McGuinness D, Malikzay A, Visconti R, Lin K, Bayne M, Monsma F, Lunn CA.

J Biomol Screen. 2009 Jan;14(1):49-58. doi: 10.1177/1087057108327329.

PMID:
19171920
10.

Screening for antiviral inhibitors of the HIV integrase-LEDGF/p75 interaction using the AlphaScreen luminescent proximity assay.

Hou Y, McGuinness DE, Prongay AJ, Feld B, Ingravallo P, Ogert RA, Lunn CA, Howe JA.

J Biomol Screen. 2008 Jun;13(5):406-14. doi: 10.1177/1087057108317060. Epub 2008 May 14.

PMID:
18480474
11.

KCa3.1: target and marker for cancer, autoimmune disorder and vascular inflammation?

Chou CC, Lunn CA, Murgolo NJ.

Expert Rev Mol Diagn. 2008 Mar;8(2):179-87. doi: 10.1586/14737159.8.2.179. Review.

PMID:
18366304
12.

Cannabinoid CB(2)-selective inverse agonist protects against antigen-induced bone loss.

Lunn CA, Fine J, Rojas-Triana A, Jackson JV, Lavey B, Kozlowski JA, Hipkin RW, Lundell DJ, Bober L.

Immunopharmacol Immunotoxicol. 2007;29(3-4):387-401.

PMID:
18075852
13.

Biology and therapeutic potential of cannabinoid CB2 receptor inverse agonists.

Lunn CA, Reich EP, Fine JS, Lavey B, Kozlowski JA, Hipkin RW, Lundell DJ, Bober L.

Br J Pharmacol. 2008 Jan;153(2):226-39. Epub 2007 Oct 1. Review.

14.

Sch35966 is a potent, selective agonist at the peripheral cannabinoid receptor (CB2) in rodents and primates.

Gonsiorek W, Lunn CA, Fan X, Deno G, Kozlowski J, Hipkin RW.

Br J Pharmacol. 2007 Aug;151(8):1262-71. Epub 2007 Jul 2.

15.

Himbacine derived thrombin receptor (PAR-1) antagonists: SAR of the pyridine ring.

Xia Y, Chackalamannil S, Clasby M, Doller D, Eagen K, Greenlee WJ, Tsai H, Agans-Fantuzzi J, Ahn HS, Boykow GC, Hsieh Y, Lunn CA, Chintala M.

Bioorg Med Chem Lett. 2007 Aug 15;17(16):4509-13. Epub 2007 Jun 15.

PMID:
17574850
16.

Optimization of triaryl bis-sulfones as cannabinoid-2 receptor ligands.

Lavey BJ, Kozlowski JA, Shankar BB, Spitler JM, Zhou G, Yang DY, Shu Y, Wong MK, Wong SC, Shih NY, Wu J, McCombie SW, Rizvi R, Wolin RL, Lunn CA.

Bioorg Med Chem Lett. 2007 Jul 1;17(13):3760-4. Epub 2007 Apr 10.

PMID:
17466519
17.

Targeting the CB2 receptor for immune modulation.

Lunn CA, Reich EP, Bober L.

Expert Opin Ther Targets. 2006 Oct;10(5):653-63. Review.

PMID:
16981823
18.

Characterization of peripheral human cannabinoid receptor (hCB2) expression and pharmacology using a novel radioligand, [35S]Sch225336.

Gonsiorek W, Hesk D, Chen SC, Kinsley D, Fine JS, Jackson JV, Bober LA, Deno G, Bian H, Fossetta J, Lunn CA, Kozlowski JA, Lavey B, Piwinski J, Narula SK, Lundell DJ, Hipkin RW.

J Biol Chem. 2006 Sep 22;281(38):28143-51. Epub 2006 Jun 5.

19.

A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo.

Lunn CA, Fine JS, Rojas-Triana A, Jackson JV, Fan X, Kung TT, Gonsiorek W, Schwarz MA, Lavey B, Kozlowski JA, Narula SK, Lundell DJ, Hipkin RW, Bober LA.

J Pharmacol Exp Ther. 2006 Feb;316(2):780-8. Epub 2005 Oct 28.

PMID:
16258021
20.

Triaryl bis-sulfones as cannabinoid-2 receptor ligands: SAR studies.

Shankar BB, Lavey BJ, Zhou G, Spitler JA, Tong L, Rizvi R, Yang DY, Wolin R, Kozlowski JA, Shih NY, Wu J, Hipkin RW, Gonsiorek W, Lunn CA.

Bioorg Med Chem Lett. 2005 Oct 15;15(20):4417-20.

PMID:
16115769
21.

Triaryl bis-sulfones as a new class of cannabinoid CB2 receptor inhibitors: identification of a lead and initial SAR studies.

Lavey BJ, Kozlowski JA, Hipkin RW, Gonsiorek W, Lundell DJ, Piwinski JJ, Narula S, Lunn CA.

Bioorg Med Chem Lett. 2005 Feb 1;15(3):783-6.

PMID:
15664857
22.

Signaling by covalent heterodimers of interferon-gamma. Evidence for one-sided signaling in the active tetrameric receptor complex.

Krause CD, Lunn CA, Izotova LS, Mirochnitchenko O, Kotenko SV, Lundell DJ, Narula SK, Pestka S.

J Biol Chem. 2000 Jul 28;275(30):22995-3004.

23.

Structural characterization of nitric oxide synthase isoforms reveals striking active-site conservation.

Fischmann TO, Hruza A, Niu XD, Fossetta JD, Lunn CA, Dolphin E, Prongay AJ, Reichert P, Lundell DJ, Narula SK, Weber PC.

Nat Struct Biol. 1999 Mar;6(3):233-42.

PMID:
10074942
24.

Purification of ADAM 10 from bovine spleen as a TNFalpha convertase.

Lunn CA, Fan X, Dalie B, Miller K, Zavodny PJ, Narula SK, Lundell D.

FEBS Lett. 1997 Jan 6;400(3):333-5.

25.

Expression of human inducible nitric oxide synthase in Escherichia coli.

Fossetta JD, Niu XD, Lunn CA, Zavodny PJ, Narula SK, Lundell D.

FEBS Lett. 1996 Jan 29;379(2):135-8.

26.

Crystal structure of a complex between interferon-gamma and its soluble high-affinity receptor.

Walter MR, Windsor WT, Nagabhushan TL, Lundell DJ, Lunn CA, Zauodny PJ, Narula SK.

Nature. 1995 Jul 20;376(6537):230-5.

PMID:
7617032
27.

Importance of the loop connecting A and B helices of human interferon-gamma in recognition by interferon-gamma receptor.

Lundell D, Lunn CA, Senior MM, Zavodny PJ, Narula SK.

J Biol Chem. 1994 Jun 10;269(23):16159-62.

28.

An active covalently linked dimer of human interferon-gamma. Subunit orientation in the native protein.

Lunn CA, Davies L, Dalgarno D, Narula SK, Zavodny PJ, Lundell D.

J Biol Chem. 1992 Sep 5;267(25):17920-4.

29.

A point mutation of human interferon gamma abolishes receptor recognition.

Lunn CA, Fossetta J, Dalgarno D, Murgolo N, Windsor W, Zavodny PJ, Narula SK, Lundell D.

Protein Eng. 1992 Apr;5(3):253-7.

PMID:
1409546
30.

A point mutation that decreases the thermal stability of human interferon gamma.

Lunn CA, Fossetta J, Murgolo N, Zavodny PJ, Lundell D, Narula SK.

Protein Eng. 1992 Apr;5(3):249-52.

PMID:
1409545
31.

Cytoplasmic and periplasmic expression of a highly basic protein, human interleukin 4, in Escherichia coli.

Lundell D, Greenberg R, Alroy Y, Condon R, Fossetta JD, Gewain K, Kastelein R, Lunn CA, Reim R, Shah C, et al.

J Ind Microbiol. 1990 Jun;5(4):215-27.

PMID:
1366607
32.

Defective Escherichia coli signal peptides function in yeast.

Pines O, Lunn CA, Inouye M.

Mol Microbiol. 1988 Mar;2(2):209-17.

PMID:
3288832
34.

Association of thioredoxin with the inner membrane and adhesion sites in Escherichia coli.

Bayer ME, Bayer MH, Lunn CA, Pigiet V.

J Bacteriol. 1987 Jun;169(6):2659-66.

35.

The effect of thioredoxin on the radiosensitivity of bacteria.

Lunn CA, Pigiet VP.

Int J Radiat Biol Relat Stud Phys Chem Med. 1987 Jan;51(1):29-38.

PMID:
3492466
36.

The catalytic active site of thioredoxin: conformation and homology with bovine pancreatic trypsin inhibitor.

Lunn CA, Pak P, Van Savage J, Pigiet V.

Biochim Biophys Acta. 1986 Jun 23;871(3):257-67.

PMID:
3707971
37.
38.

Secretion cloning vectors for guiding the localization of proteins in vivo.

Lunn CA, Takahara M, Inouye M.

Curr Top Microbiol Immunol. 1986;125:59-74. No abstract available.

PMID:
3091325
39.

Use of secretion cloning vectors for guiding the localization of proteins in Escherichia coli.

Lunn CA, Takahara M, Inouye M.

Methods Enzymol. 1986;125:138-49. No abstract available.

PMID:
3012256
40.

An alternate pathway for the processing of the prolipoprotein signal peptide in Escherichia coli.

Ghrayeb J, Lunn CA, Inouye S, Inouye M.

J Biol Chem. 1985 Sep 15;260(20):10961-5.

41.

Amplification and purification of plasmid-encoded thioredoxin from Escherichia coli K12.

Lunn CA, Kathju S, Wallace BJ, Kushner SR, Pigiet V.

J Biol Chem. 1984 Aug 25;259(16):10469-74.

42.

Localization of thioredoxin from Escherichia coli in an osmotically sensitive compartment.

Lunn CA, Pigiet VP.

J Biol Chem. 1982 Oct 10;257(19):11424-30. No abstract available.

43.

Isolation and characterization of a protease-nicked thioredoxin.

McEvoy M, Lantz C, Lunn CA, Pigiet V.

J Biol Chem. 1981 Jul 10;256(13):6646-50.

44.

Characterization of a high activity form of ribonucleoside diphosphate reductase from Escherichia coli.

Lunn CA, Pigiet V.

J Biol Chem. 1979 Jun 25;254(12):5008-14. No abstract available.

Supplemental Content

Support Center